Sernova Biotherapeutics Inc
SVA.TO
TSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.36M | 5.66M | 5.93M | 6.09M | 6.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.70M | 12.40M | 15.08M | 19.25M | 23.30M |
| Operating Income | -10.70M | -12.40M | -15.08M | -19.25M | -23.30M |
| Income Before Tax | -11.21M | -13.22M | -15.77M | -20.47M | -23.68M |
| Income Tax Expenses | 6.20K | 50.90K | 35.50K | 9.60K | 5.10K |
| Earnings from Continuing Operations | -11.21 | -13.27 | -15.81 | -20.48 | -23.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.21M | -13.27M | -15.81M | -20.48M | -23.69M |
| EBIT | -10.70M | -12.40M | -15.08M | -19.25M | -23.30M |
| EBITDA | -10.51M | -12.23M | -14.86M | -19.00M | -23.00M |
| EPS Basic | -0.03 | -0.04 | -0.05 | -0.07 | -0.08 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 |
| EPS Diluted | -0.03 | -0.04 | -0.05 | -0.07 | -0.08 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 |
| Average Basic Shares Outstanding | 1.31B | 1.30B | 1.28B | 1.25B | 1.23B |
| Average Diluted Shares Outstanding | 1.31B | 1.30B | 1.28B | 1.25B | 1.23B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |